A detailed history of Kendall Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Kendall Capital Management holds 32,727 shares of ABBV stock, worth $6.37 Million. This represents 1.91% of its overall portfolio holdings.

Number of Shares
32,727
Previous 32,853 0.38%
Holding current value
$6.37 Million
Previous $5.98 Million 6.17%
% of portfolio
1.91%
Previous 2.12%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$154.79 - $180.76 $19,503 - $22,775
-126 Reduced 0.38%
32,727 $5.61 Million
Q1 2024

May 10, 2024

SELL
$159.82 - $182.1 $98,289 - $111,991
-615 Reduced 1.84%
32,853 $5.98 Million
Q4 2023

Jan 26, 2024

BUY
$137.6 - $154.97 $142,140 - $160,084
1,033 Added 3.18%
33,468 $5.19 Million
Q3 2023

Oct 31, 2023

BUY
$133.59 - $154.65 $26,050 - $30,156
195 Added 0.6%
32,435 $4.84 Million
Q2 2023

Jul 28, 2023

BUY
$132.51 - $164.9 $96,864 - $120,541
731 Added 2.32%
32,240 $4.34 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $50,179 - $57,789
347 Added 1.11%
31,509 $5.02 Million
Q4 2022

Jan 30, 2023

SELL
$138.31 - $165.87 $130,979 - $157,078
-947 Reduced 2.95%
31,162 $5.04 Million
Q3 2022

Nov 02, 2022

SELL
$134.21 - $153.93 $49,657 - $56,954
-370 Reduced 1.14%
32,109 $4.31 Million
Q2 2022

Jul 29, 2022

SELL
$137.62 - $174.96 $116,288 - $147,841
-845 Reduced 2.54%
32,479 $4.97 Million
Q1 2022

May 06, 2022

SELL
$131.98 - $163.75 $239,543 - $297,206
-1,815 Reduced 5.17%
33,324 $5.4 Million
Q4 2021

Jan 28, 2022

SELL
$107.43 - $135.93 $85,514 - $108,200
-796 Reduced 2.22%
35,139 $4.76 Million
Q3 2021

Nov 05, 2021

SELL
$106.4 - $120.78 $98,952 - $112,325
-930 Reduced 2.52%
35,935 $3.88 Million
Q2 2021

Jul 30, 2021

SELL
$105.21 - $117.21 $66,808 - $74,428
-635 Reduced 1.69%
36,865 $4.15 Million
Q1 2021

May 05, 2021

BUY
$102.3 - $112.62 $31,713 - $34,912
310 Added 0.83%
37,500 $4.06 Million
Q4 2020

Feb 08, 2021

SELL
$80.49 - $108.67 $26,964 - $36,404
-335 Reduced 0.89%
37,190 $3.99 Million
Q3 2020

Oct 22, 2020

BUY
$85.91 - $100.83 $74,741 - $87,722
870 Added 2.37%
37,525 $3.29 Million
Q2 2020

Jul 30, 2020

BUY
$73.37 - $98.18 $262,297 - $350,993
3,575 Added 10.81%
36,655 $3.6 Million
Q1 2020

Apr 27, 2020

SELL
$64.5 - $97.79 $187,437 - $284,177
-2,906 Reduced 8.08%
33,080 $2.52 Million
Q4 2019

Jan 24, 2020

BUY
$72.13 - $90.25 $73,716 - $92,235
1,022 Added 2.92%
35,986 $3.19 Million
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $161,858 - $194,600
2,570 Added 7.93%
34,964 $2.65 Million
Q2 2019

Aug 09, 2019

BUY
$65.7 - $83.98 $57,684 - $73,734
878 Added 2.79%
32,394 $2.36 Million
Q1 2019

May 08, 2019

BUY
$77.14 - $90.79 $103,753 - $122,112
1,345 Added 4.46%
31,516 $2.54 Million
Q4 2018

Feb 13, 2019

SELL
$77.85 - $96.01 $37,601 - $46,372
-483 Reduced 1.58%
30,171 $2.78 Million
Q3 2018

Oct 29, 2018

BUY
$88.91 - $98.84 $174,530 - $194,022
1,963 Added 6.84%
30,654 $2.9 Million
Q2 2018

Jul 27, 2018

BUY
$89.78 - $106.23 $86,637 - $102,511
965 Added 3.48%
28,691 $2.66 Million
Q1 2018

May 14, 2018

SELL
$92.01 - $123.21 $7,820 - $10,472
-85 Reduced 0.31%
27,726 $2.62 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $2.49 Million - $2.73 Million
27,811
27,811 $2.69 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Kendall Capital Management Portfolio

Follow Kendall Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kendall Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Kendall Capital Management with notifications on news.